| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.063 | 0.4 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.4 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.069 | 0.4 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | 0.25 | 0.4 |
| mRNA | tubastatin A | GDSC1000 | pan-cancer | AAC | -0.038 | 0.4 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | 0.038 | 0.4 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.27 | 0.4 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | 0.04 | 0.4 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.4 |